Sugi Predict

Sugi Predict / Compounds / Biphenyl

Biphenyl

Biphenyl

SCHEMBL598126

[MgH2].c1ccc(-c2ccccc2)cc1.c1ccc(-c2ccccc2)cc1

nearest known ligand 0.90

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.90
▸ MAPK1 P28482 2/20 0.56
▸ TAAR1 Q96RJ0 2/20 0.56
▸ CYP1A2 P05177 1/20 0.56
▸ CYP3A4 P08684 1/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ NOTUM Q6P988 1/20 0.56
▸ MMP3 P08254 1/20 0.56
▸ BCL2L1 Q07817 1/20 0.56
▸ NPC1 O15118 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ ATM Q13315 1/20 0.50
▸ SLC22A2 O15244 1/20 0.50
▸ SLC22A1 O15245 1/20 0.50
▸ SLC22A3 O75751 1/20 0.50
▸ SLC6A4 P31645 1/20 0.50
▸ MAOA P21397 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL1225930 1.00 ALDH1A1 (0.90) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL11524760 0.95 ALDH1A1 (0.82) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL3277132 0.95 ALDH1A1 (0.82) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL11258543 0.95 ALDH1A1 (0.82) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL164 0.95 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL2548048 0.95 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL4002609 0.95 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL28890607 0.95 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
Biphenyl SCHEMBL1358618 0.95 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4
SCHEMBL30629023 0.95 ALDH1A1 (1.00) ALDH1A1MAPK1TAAR1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624163-B2 Process for preparing intermediates useful in the manufacture of NEP inhibitors NOVARTIS AG (CH) 2017-04-18 — — US claimed
US-20150210632-A1 NEW PROCESS NOVARTIS AG (CH) 2015-07-30 — — US claimed
EP-2890672-A1 NEW PROCESS Novartis AG (CH) 2015-07-08 — — EP claimed
WO-2014032627-A1 NEW PROCESS ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD (CN) 2014-03-06 — — WO claimed
CN-109415308-B Novel method for early-stage sabcomet intermediate 诺华股份有限公司 2022-09-06 — — CN disclosed
US-20190256454-A1 NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES NOVARTIS PHARMA AG (CH) 2019-08-22 — — US disclosed
EP-3481799-A1 NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES Novartis AG (CH) 2019-05-15 — — EP disclosed
EP-2890672-B1 PROCESSES FOR PREPARING INTERMEDIATES FOR THE MANUFACTURE OF NEP INHIBITORS NOVARTIS AG (CH) 2018-05-30 — — EP disclosed
WO-2018007919-A1 NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES NOVARTIS AG (CH) 2018-01-11 — — WO disclosed
US-9624163-B2 Process for preparing intermediates useful in the manufacture of NEP inhibitors NOVARTIS AG (CH) 2017-04-18 — — US disclosed
EP-2121578-B1 PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID NOVARTIS AG (CH) 2016-08-10 — — EP disclosed
US-9206116-B2 Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid NOVARTIS AG (CH) 2015-12-08 — — US disclosed
EP-1651682-A1 PROCESS FOR THE PREPARATION OF A METAL-ORGANIC COMPOUND COMPRISING AT LEAST ONE IMINE LIGAND DSM IP Assets B.V. (NL) 2006-05-03 — — EP disclosed
EP-1651681-A1 PROCESS FOR THE PREPARATION OF A METALLOORGANIC COMPOUND COMPRISING AT LEAST ONE IMINE LIGAND DSM IP Assets B.V. (NL) 2006-05-03 — — EP disclosed
WO-2005090418-A1 POLIMERIZATION CATALYST COMPRISING AN AMIDINE LIGAND DSM IP ASSETS B.V. (NL) 2005-09-29 — — WO disclosed
WO-2005014664-A1 PROCESS FOR THE PREPARATION OF A METAL-ORGANIC COMPOUND COMPRISING AT LEAST ONE IMINE LIGAND DSM IP ASSETS B.V. (NL) 2005-02-17 — — WO disclosed
WO-2005014666-A1 PROCESS FOR THE PREPARATION OF A METAL-ORGANIC COMPOUND COMPRISING AT LEAST ONE IMINE LIGAND DSM IP ASSETS B.V. (NL) 2005-02-17 — — WO disclosed
WO-2005014665-A1 PROCESS FOR THE PREPARATION OF A METALLOORGANIC COMPOUND COMPRISING AT LEAST ONE IMINE LIGAND DSM IP ASSETS B.V. (NL) 2005-02-17 — — WO disclosed
WO-2005014663-A1 PROCESS FOR THE PREPARATION OF AN METALLOORGANIC COMPOUND COMPRISING AT LEAST ONE IMINE LIGAND DSM IP ASSETS B.V. (NL) 2005-02-17 — — WO disclosed
EP-1506974-A1 Process for the preparation of a metalloorganic compound comprising at least one imine ligand DSM IP Assets B.V. (NL) 2005-02-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210632-A1 NEW PROCESS MME, DNPEP, ACE ALDH1A1 389/4885MAPK1 2628/4885TAAR1 583/4885
US-20190256454-A1 NEW PROCESS FOR EARLY SACUBITRIL INTERMEDIATES MME, ACE, DNPEP ALDH1A1 261/4885MAPK1 3124/4885TAAR1 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback